Clinical trial readout dates for Alnylam Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is April 2027.
| Phase 1/2 ALN-2232 Obesity · NCT07463846 | April 2027 Recruiting |
| Phase 2 ALN-4324 Type 2 Diabetes Mellitus (T2DM) · NCT07465224 | May 2027 Ongoing |
| Phase 2 ALN-6400 Von Willebrand Disease (VWD); Heavy Menstrual Bleeding (HMB) · NCT07575308 | June 2027 Recruiting |
| Phase 2 ALN-APP Cerebral Amyloid Angiopathy · NCT06393712 | August 2027 Ongoing |
| Phase 1/2 ALN-4324 Obese or Overweight Healthy Volunteers; Type 2 Diabetes Mellitus (T2DM) · NCT06845202 | August 2027 Ongoing |
| Phase 3 Nucresiran Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; hATTR-PN · NCT07223203 | December 2027 Recruiting |
| Phase 1/2 ALN-6400 Hereditary Hemorrhagic Telangiectasia · NCT06659640 | January 2028 Ongoing |
| Phase 3 Vutrisiran Transthyretin Amyloidosis (ATTR) With Cardiomyopathy · NCT06679946 | March 2028 Enrolling |
Alnylam Pharmaceuticals Inc. reported $3.59B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-29). It reported net income of $2.17B for that quarter.
| 8-K Other Events — often topline trial data | 2026-11-05 |
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-10-29 |